PepTrackevidence-graded reference
Tesamorelin
fig.1 — stylized molecular motif
GH secretagogue

Tesamorelin

Egrifta · Egrifta SV · Egrifta WR

Fastest-rising GH/anti-aging search (+49% in 6 mo); FDA-approved credibility anchor; growing off-label visceral-fat use.

Evidence
AFDA-approved RCTs
Status
FDA-approvedas of 2026-06
Approval
FDA-approved
Category
GH secretagogue
Route
Subcutaneous
Demand rank
#9 most-searched
01Dosing & Protocol
Typical · reference only
Label: Egrifta SV 1.4 mg SC daily / WR 1.28 mg / original 2 mg (equivalent exposure - DO NOT stack/convert). Off-label community: 1-2 mg/day
Titration
None on label (full dose day one)
Reconstitution — illustrative, not a recommendation
Egrifta SV: 2 mg vial + 0.5 mL Sterile Water = 4 mg/mL; 1.4 mg = 35 U. WR: 11.6 mg + 1.3 mL BAC ~ 8 mg/mL; 1.28 mg = 16 U. Applying SV's 35 U to a WR vial = ~2.8 mg overdose.
Units are not milligrams. mg-vs-mcg confusion drives documented 5–1000× overdoses — always recompute for your own vial.
02Regulatory Status
Removal from Category 2 ≠ legal to compound ≠ FDA-approved. Off-label compounded channel threatened by the 'essentially a copy' rule.
Pre-clinical
Phase 1
Phase 2
Phase 3
Approved
Status
FDA-approved
503A bulks
Not on the bulks list
Category 2
n/a (approved); NOT among the removed peptides
PCAC review
none scheduled
WADA
Prohibited
03Evidence — the honest read
What the evidence actually shows

Approved for HIV-lipodystrophy only (~10-11% VAT reduction at 26 wks; '15-18%' overstates pivotal endpoints). Anti-aging use is extrapolation.

04Safety
Contraindications
  • Active malignancyhard stop
  • Hypothalamic-pituitary axis disruptionhard stop
  • Pregnancyhard stop
  • Hypersensitivity (incl. mannitol)
Key interactions
  • Corticosteroids/anticonvulsants/cyclosporine (GH alters CYP450; adrenal-replacement patients may need higher doses)
  • Antidiabetics (worsens glucose tolerance)
Serious signals
  • Glucose/diabetes worsening (new-onset diabetes HR ~3.3)
  • IGF-1 STOP RULE: discontinue if IGF-1 SDS >2 / Z>=3 persists
Monitoring
IGF-1 at baseline + periodically WITH the SDS>2 stop rule; fasting glucose/HbA1c.
05Related in GH secretagogue
CJC-1295 / Ipamorelin
human trials
grade B →
Sermorelin
human trials
grade B →
06Sources
1DailyMed Egrifta SV/WR
＋PepTrack research dossier — iterations 1–4, 584 de-duplicated sources, adversarially verified.
Not medical or legal advice. Educational / harm-reduction reference. Regulatory and dosing claims in this field move monthly — re-verify against primary sources (FDA docket FDA-2025-N-6895, DailyMed, ClinicalTrials.gov) before acting.
Last reviewed — 2026-06-13 · confidence: med-high
← All peptides
GH secretagogue

Tesamorelin

Egrifta · Egrifta SV · Egrifta WR

Fastest-rising GH/anti-aging search (+49% in 6 mo); FDA-approved credibility anchor; growing off-label visceral-fat use.

Evidence
A
FDA-approved RCTs
Status
FDA-approved
as of 2026-06
FDA approval
Approved
on-label use exists
Route
Subcutaneous
FDA label
Demand
#9
most-searched
WADA
Prohibited
tested athletes — avoid
01

Dosing & protocol

FDA label. Dosing reference per the FDA label.
Typical — reference only

Label: Egrifta SV 1.4 mg SC daily / WR 1.28 mg / original 2 mg (equivalent exposure - DO NOT stack/convert). Off-label community: 1-2 mg/day

Worked reconstitution example

Egrifta SV: 2 mg vial + 0.5 mL Sterile Water = 4 mg/mL; 1.4 mg = 35 U. WR: 11.6 mg + 1.3 mL BAC ~ 8 mg/mL; 1.28 mg = 16 U. Applying SV's 35 U to a WR vial = ~2.8 mg overdose.

Titration

None on label (full dose day one)

Units are not milligrams. mg-vs-mcg confusion drives documented 5–1000× overdoses — always recompute for your own vial (use the calculator →).
02

Regulatory status

Removal from Category 2 ≠ legal to compound ≠ FDA-approved. Off-label compounded channel threatened by the 'essentially a copy' rule.
Pre-clinical
Phase 1
Phase 2
Phase 3
Approved
StatusFDA-approved
503A bulksNot on the bulks list
Category 2 (2026)n/a (approved); NOT among the removed peptides
PCAC reviewnone scheduled
WADAProhibited (S0)
03

Evidence — the honest read

AFDA-approved RCTs

Approved for HIV-lipodystrophy only (~10-11% VAT reduction at 26 wks; '15-18%' overstates pivotal endpoints). Anti-aging use is extrapolation.

04

Safety

Contraindications
  • Active malignancyhard stop
  • Hypothalamic-pituitary axis disruptionhard stop
  • Pregnancyhard stop
  • Hypersensitivity (incl. mannitol)
Key interactions
  • Corticosteroids/anticonvulsants/cyclosporine (GH alters CYP450; adrenal-replacement patients may need higher doses)
  • Antidiabetics (worsens glucose tolerance)
Serious signals
  • Glucose/diabetes worsening (new-onset diabetes HR ~3.3)
  • IGF-1 STOP RULE: discontinue if IGF-1 SDS >2 / Z>=3 persists
Monitoring

IGF-1 at baseline + periodically WITH the SDS>2 stop rule; fasting glucose/HbA1c.

06

Sources

01DailyMed Egrifta SV/WR
＋PepTrack research dossier — iterations 1–4, 584 de-duplicated sources, adversarially verified.
Not medical or legal advice. Educational / harm-reduction reference. Regulatory and dosing claims in this field move monthly — re-verify against primary sources (FDA docket FDA-2025-N-6895, DailyMed, ClinicalTrials.gov) before acting.
Last reviewed — 2026-06-13 · confidence: med-high